This article reveals how AI and big data can improve pharmaceutical innovation and health surveillance, suggesting interdisciplinary strategies.
The integration of artificial intelligence (AI), big data analytics, wearable health devices, and biotechnology is driving a transformative change in pharmaceutical innovation and global health. This article consolidates four fundamental research areas encompassing AI-based drug discovery, real-time cardiovascular disease monitoring via wearables, big data frameworks for antimicrobial resistance (AMR) surveillance, and biotechnology-driven strategy models for global competitiveness. These papers collectively illustrate how generative algorithms, predictive analytics, and biotechnology frameworks can expedite medication development, enhance preventative healthcare, and fortify global health security. This article, supported by over 30 scientific papers, presents an integrated conceptual framework that combines computational intelligence, biomedical data streams, and biotechnology market strategies into a unified model for next-generation pharmaceutical innovation. The results underscore the necessity for interdisciplinary collaboration, ethical governance, and strategic policymaking to convert technical advancements into sustainable global health solutions.
No takes yet. Share an insight, caveat, or question.
Hossain et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: